Is continuous ketamine infusion safe for patients on a general medical floor?

Continuous Ketamine on General Medical Floors: Safety Considerations

Continuous ketamine infusion can be safely administered on general medical floors for acute pain management when proper protocols, monitoring, and trained staff are in place, but this requires careful patient selection and adherence to specific safety parameters.

Key Safety Requirements

The FDA label explicitly mandates that ketamine "should be administered by or under the direction of physicians experienced in the administration of general anesthetics, maintenance of a patent airway, and oxygenation and ventilation" with emergency airway equipment immediately available 1. However, this does not necessarily restrict use to ICU settings when appropriate safeguards exist.

Evidence Supporting Medical Floor Use

Real-world implementation data demonstrates feasibility outside the ICU. A 2023 study successfully implemented a ketamine infusion protocol for acute pain on medical-surgical wards, demonstrating that "ketamine infusions on the medical-surgical ward are safe and cost-effective when an established acute pain service protocol is followed" 2. This represents the most direct evidence addressing your specific question.

The protocol requires:

• Established acute pain service oversight
• Trained nursing staff with ongoing support
• Clear monitoring parameters
• Defined escalation pathways

Dosing and Monitoring Parameters

For general floor use, subanesthetic doses are critical for safety:

• Bolus doses: <0.35 mg/kg
• Continuous infusion: 0.5-1 mg/kg/hour (typically 0.1-0.23 mcg/kg/hour in practice)
• No intensive monitoring required at these doses 3

Recent ICU data showed median infusion rates of 0.11 mcg/kg/hour were hemodynamically safe without increasing vasopressor requirements 4. The 2018 Critical Care Medicine guidelines suggest low-dose ketamine (0.5 mg/kg IV push followed by 1-2 μg/kg/min infusion) as adjunctive therapy 5.

Critical Safety Considerations

Respiratory Monitoring

The primary safety concern is respiratory depression, particularly with rapid administration or overdosage 1. However, ketamine has significant advantages over traditional sedatives:

• Preserves airway reflexes (unlike propofol or benzodiazepines)
• Does not suppress respiratory drive at subanesthetic doses
• ICU studies show ketamine/midazolam caused less hypoxemia (6%) compared to fentanyl/midazolam (24%) 6, 7

Mandatory monitoring includes:

• Continuous pulse oximetry
• Frequent respiratory rate assessment
• Neurological status checks
• Blood pressure and heart rate monitoring 1

Cardiovascular Effects

Ketamine produces sympathomimetic effects that can be beneficial or harmful depending on patient selection 1:

Contraindications:

• Uncontrolled cardiovascular disease
• Ischemic heart disease
• Cerebrovascular disease
• Uncontrolled hypertension

Monitoring findings from floor-based studies:

• Hypotension (SBP <90 mmHg) occurred in 31.8% receiving ketamine alone 8
• Hypertension (SBP >180 mmHg) occurred in 39.3% 8
• Heart rate typically decreased during infusion 4

Neuropsychiatric Effects

Emergence reactions and psychotomimetic effects (dysphoria, nightmares, hallucinations) are dose-dependent 9, 1. These can be mitigated by:

• Using lower recommended dosages
• Co-administering benzodiazepines during induction
• Minimizing verbal, tactile, and visual stimulation during recovery
• Avoiding use in patients with active psychosis 3, 1

The 2024 BMJ guidelines note concerns about delirium, nightmares, and laryngospasm, though these may be reduced at subanesthetic doses 10.

Additional Monitoring Requirements

For recurrent dosing (which applies to continuous infusions), the FDA mandates:

• Baseline liver function tests (alkaline phosphatase, gamma-glutamyl transferase)
• Periodic monitoring during treatment 1

This stems from associations with hepatobiliary dysfunction and biliary duct dilatation with repeated use 1.

Patient Selection Criteria

Ideal candidates for medical floor ketamine:

• Severe acute pain unresponsive to other modalities
• Patients at high risk for opioid-related adverse events
• Postoperative patients requiring opioid-sparing strategies
• Hemodynamically stable patients
• No contraindications (see above)

Exclude patients with:

• Elevated intracranial pressure (requires monitored setting with frequent neurologic assessments) 1
• Severe liver dysfunction
• High intraocular pressure
• Pregnancy
• Active psychosis 3, 1

Practical Implementation Algorithm

1. Pre-initiation assessment:

   • Verify trained staff availability
   • Confirm monitoring equipment functional
   • Ensure emergency airway equipment accessible
   • Obtain baseline vital signs and LFTs
   • Screen for contraindications

2. Initiation:

   • Start with low-dose protocol (0.5 mg/kg bolus, then 1-2 μg/kg/min)
   • Administer slowly over 60 seconds if bolus given
   • Consider benzodiazepine co-administration

3. Ongoing monitoring:

   • Continuous pulse oximetry
   • Vital signs every 15-30 minutes initially, then hourly when stable
   • Sedation level assessment using validated scales
   • Neurological checks for emergence reactions

4. Escalation criteria:

   • Respiratory rate <10 or >30
   • SpO2 <90% despite supplemental oxygen
   • Severe hypertension or hypotension
   • Significant emergence reactions
   • Any airway compromise

Opioid-Sparing Benefits

Multiple studies demonstrate ketamine's value as an adjunct:

• Reduced morphine consumption by 22 mg in postoperative ICU patients 5
• Decreased opioid requirements in medical/cardiac ICU patients from 3.0 to 1.0 mcg/kg/h fentanyl equivalent 4
• Fewer days of intermittent benzodiazepine use 11

The 2014 ICU palliative care guidelines support sub-anesthetic ketamine doses to reduce overall opioid requirements, particularly for refractory pain 9.

Common Pitfalls to Avoid

1. Rapid administration: Always administer slowly to prevent respiratory depression and enhanced vasopressor response 1

2. Inadequate monitoring: Never use without continuous pulse oximetry and frequent vital sign checks

3. Wrong concentration: The 100 mg/mL concentration must be diluted before IV administration 1

4. Ignoring drug interactions: Exercise extreme caution with concurrent opioids, benzodiazepines, or CNS depressants—can cause profound sedation, respiratory depression, coma, or death 1

5. Lack of protocol: Implementation without established acute pain service protocols and trained nursing staff significantly increases risk 2

6. Inadequate staffing: Requires nurses trained in ketamine administration and recognition of complications

Bottom Line

Continuous ketamine infusion is safe on general medical floors when administered through a structured protocol with appropriate patient selection, trained staff, and adequate monitoring. The evidence supports this practice for acute pain management, particularly as an opioid-sparing strategy 2. However, this is not appropriate for all institutions—success requires institutional commitment to protocol development, staff education, and ongoing quality monitoring. Without these elements in place, ketamine should remain restricted to higher acuity settings where more intensive monitoring is standard.